Inhibitex, Inc. (Nasdaq: INHX) (the “Company”), a biopharmaceutical company focused on developing products to treat serious infectious diseases, announced today that it has received notice from The NASDAQ Stock Market ("Nasdaq") stating that, as the closing bid price of the Company’s common stock has been at or above $1.00 per share for 10 consecutive business days, the Company has regained compliance with Nasdaq’s Listing Rule 5550(a)(2) and its delisting matter has been closed. Accordingly, the Company is currently in full compliance with all listing requirements of the Nasdaq Capital Market.

For additional information about the Company, please visit www.inhibitex.com.

Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Inhibitex, Inc. (MM) Charts.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Inhibitex, Inc. (MM) Charts.